AbbVie, Coherus in legal battle over Humira biosimilar
vzphotos/iStock Editorial via Getty Images
AbbVie (ABBV) has challenged Coherus BioSciences’ (NASDAQ:CHRS) plans to introduce an off-patent version of its blockbuster arthritis therapy Humira, according to a regulatory filing on Thursday.
AbbVie (ABBV) reached a 52-week low early this month after Coherus (CHRS) announced it would launch a Humira biosimilar, branded as Yusimrytm, in July in partnership with Mark Cuban Cost Plus Drug Company at a sharp discount.
In the wake of the announcement, AbbVie (ABBV) has alleged that Coherus (CHRS) violated a settlement and license agreement between the companies related to a Humira biosimilar.
In reaction, Coherus (CHRS) has sent a written response denying the allegation and requesting further details from AbbVie (ABBV).
CHRS has filed a motion for a temporary restraining order against the pharma giant in the Delaware Court of Chancery on June 13, the company said, adding that the same day, AbbVie (ABBV) also filed a preliminary injunction.
However, after negotiations, on June 14, AbbVie (ABBV) has agreed it would not attempt to end the agreement between the companies under certain conditions.